PBM

Propel Bio Management Portfolio holdings

AUM $191M Turnover 36.59%
1-Year Est. Return 102.42%
This Fund
S&P 500
This Quarter Est. Return
+28.07%
1 Year Est. Return
+102.42%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$121M
AUM Growth
–
Cap. Flow
+$104M
Cap. Flow %
85.99%
Top 10 Hldgs %
71.63%
Holding
34
New
34
Increased
–
Reduced
–
Closed
–
Avg Time Held
0 years
Top 10 Avg Time Held
0 years
Top 20 Avg Time Held
0 years

Top Buys

Rank Stock Value
1
PAGP icon
Plains GP Holdings
PAGP
+$21.7M
2
APLT icon
Applied Therapeutics
APLT
+$13.4M
3
TCRX icon
TScan Therapeutics
TCRX
+$9.55M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$5.26M
5
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$5.06M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 64.31%
2 Energy 18.15%
3 Miscellaneous 15.02%
4 Technology 2.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PAGP icon
1
Plains GP Holdings
PAGP
$5.37B
$21.9M 18.15%
+1,372,360
New +$21.7M
2023 Q4
0 quarters
APLT icon
2
DELISTED
Applied Therapeutics
APLT
$18M 14.93%
+5,374,982
New +$13.4M
2023 Q4
0 quarters
TCRX icon
3
TScan Therapeutics
TCRX
$14.3M
$12.2M 10.09%
+2,087,139
New +$9.55M
2023 Q4
0 quarters
MDGL icon
4
Madrigal Pharmaceuticals
MDGL
$10.6B
$6.95M 5.76%
+30,032
New +$5.26M
2023 Q4
0 quarters
CRNX icon
5
DELISTED
Crinetics Pharmaceuticals
CRNX
$5.87M 4.87%
+165,000
New +$5.06M
2023 Q4
0 quarters
FULC icon
6
Fulcrum Therapeutics
FULC
$280M
$5.06M 4.2%
+750,000
New +$3.33M
2023 Q4
0 quarters
PHAT icon
7
Phathom Pharmaceuticals
PHAT
$599M
$4.05M 3.35%
+443,047
New +$3.82M
2023 Q4
0 quarters
DAWN icon
8
DELISTED
Day One Biopharmaceuticals
DAWN
$3.95M 3.28%
+270,664
New +$3.28M
2023 Q4
0 quarters
ARDX icon
9
Ardelyx
ARDX
$824M
$3.68M 3.05%
+594,174
New +$2.67M
2023 Q4
0 quarters
LONA icon
10
LeonaBio Inc
LONA
$50.8M
$3.63M 3.01%
+149,279
New +$2.65M
2023 Q4
0 quarters
TSAT icon
11
Telesat
TSAT
$673M
$3.03M 2.51%
+290,781
New +$3.25M
2023 Q4
0 quarters
HIGH icon
12
Simplify Enhanced Income ETF
HIGH
$58M
$2.95M 2.45%
+120,221
New +$2.98M
2023 Q4
0 quarters
AKRO icon
13
DELISTED
Akero Therapeutics
AKRO
$2.34M 1.94%
+100,052
New +$1.97M
2023 Q4
0 quarters
BSV icon
14
Vanguard Short-Term Bond ETF
BSV
$45.4B
$2.13M 1.77%
+27,712
New +$2.1M
2023 Q4
0 quarters
IBDP icon
15
DELISTED
iShares iBonds Dec 2024 Term Corporate ETF
IBDP
$2.13M 1.76%
+85,442
New +$2.12M
2023 Q4
0 quarters
MBB icon
16
iShares MBS ETF
MBB
$35.7B
$2.11M 1.75%
+22,400
New +$2.01M
2023 Q4
0 quarters
MIRM icon
17
Mirum Pharmaceuticals
MIRM
$5.19B
$2.07M 1.71%
+70,000
New +$2.12M
2023 Q4
0 quarters
MRNS icon
18
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.96M 1.62%
+180,100
New +$1.35M
2023 Q4
0 quarters
KURA icon
19
Kura Oncology
KURA
$855M
$1.87M 1.55%
+130,000
New +$1.28M
2023 Q4
0 quarters
RNAM
20
DELISTED
Avidity Biosciences
RNAM
$1.62M 1.34%
+178,500
New +$1.19M
2023 Q4
0 quarters
KYMR icon
21
Kymera Therapeutics
KYMR
$8.88B
$1.43M 1.19%
+56,359
New +$1.01M
2023 Q4
0 quarters
SPSB icon
22
State Street SPDR Portfolio Short Term Corporate Bond ETF
SPSB
$11.2B
$1.36M 1.13%
+45,695
New +$1.34M
2023 Q4
0 quarters
KYN icon
23
Kayne Anderson Energy Infrastructure Fund
KYN
$2.4B
$1.29M 1.07%
+147,033
New +$1.23M
2023 Q4
0 quarters
EIGR
24
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$986K 0.82%
+146,381
New +$1.29M
2023 Q4
0 quarters
STRO icon
25
Sutro Biopharma
STRO
$174M
$837K 0.69%
+19,500
New +$619K
2023 Q4
0 quarters
1
2

Similar funds

CFG
Capital Financial Group Greenwood Village, Colorado $191M AUM
MWM
Magnolia Wealth Management Dothan, Alabama $191M AUM 17.58% 1-Year Est. Return
ALWM
Andrews Lucia Wealth Management Danville, California $191M AUM 24.94% 1-Year Est. Return
PFA
Pillar Financial Advisors Louisville, Kentucky $191M AUM 21.21% 1-Year Est. Return
NWM
Navigoe Wealth Management Redondo Beach, California $191M AUM 25.21% 1-Year Est. Return
MCA
Martin Capital Advisors San Antonio, Texas $191M AUM 42.42% 1-Year Est. Return
EMCIP
Ewing Morris & Co Investment Partners Toronto, Ontario, Canada $191M AUM 23.88% 1-Year Est. Return
HPM
H. Partners Management New York $191M AUM 5.95% 1-Year Est. Return

Propel Bio Management's Q4 2023 Portfolio in Review

Q4 2023 is the first quarter with a 13F filing on record for Propel Bio Management, which disclosed 34 positions worth $121M. Its ten largest holdings account for 72% of the portfolio.

Its largest position is Plains GP Holdings: 1,372,360 shares worth $21.9M.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, followed by Energy and Miscellaneous.

  • Propel Bio Management's largest Q4 2023 buy was Plains GP Holdings: 1,372,360 shares worth $21.9M.
  • Propel Bio Management's ten largest holdings make up 72% of its $121M portfolio in Q4 2023.
  • Propel Bio Management disclosed 34 positions in Q4 2023, its first 13F filing on record.

Based on Propel Bio Management's 13F filing for Q4 2023, filed 14 Feb 2024.